This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Cardiovascular System  • Quality of Care  • Patient Safety/ Medical Error  • Health Care Reform  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Michael R. Law, PhD; Stephen B. Soumerai, ScD; Alyce S. Adams, PhD; Sumit R. Majumdar, MD, MPH

Arch Intern Med. 2009;169(21):1969-1974.

Background  Direct-to-consumer advertising (DTCA) is assumed to be a major driver of rising pharmaceutical costs. Yet, research on how it affects costs is limited. Therefore, we studied clopidogrel, a commonly used and heavily marketed antiplatelet agent, which was first sold in 1998 and first direct-to-consumer advertised in 2001.

Methods  We examined pharmacy data from 27 Medicaid programs from 1999 through 2005. We used interrupted time series analysis to analyze changes in the number of units dispensed, cost per unit dispensed, and total pharmacy expenditures after DTCA initiation.

Results  In 1999 and 2000, there was no DTCA for clopidogrel; from 2001 through 2005, DTCA spending exceeded $350 million. Direct-to-consumer advertising did not change the preexisting trend in the number of clopidogrel units dispensed per 1000 enrollees (P = .10). However, there was a sudden and sustained increase in cost per unit of $0.40 after DTCA initiation (95% confidence interval, $0.31-$0.49; P < .001), leading to an additional $40.58 of pharmacy costs per 1000 enrollees per quarter thereafter (95% confidence interval, $22.61-$58.56; P < .001). Overall, this change resulted in an additional $207 million in total pharmacy expenditures.

Conclusions  Direct-to-consumer advertising was not associated with an increase in clopidogrel use over and above preexisting trends. However, Medicaid pharmacy expenditures increased substantially after the initiation of DTCA because of a concomitant increase in the cost per unit. If drug price increases after DTCA initiation are common, there are important implications for payers and for policy makers in the United States and elsewhere.

Author Affiliations: Centre for Health Services and Policy Research, The University of British Columbia, Vancouver, Canada (Dr Law); Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts (Drs Soumerai); Division of Research, Kaiser Permanente, Oakland California (Dr Adams); and Division of General Internal Medicine, Department of Medicine, University of Alberta, Edmonton, Canada (Dr Majumdar).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance
Joseph S. Ross, David Madigan, Kevin P. Hill, David S. Egilman, Yongfei Wang, and Harlan M. Krumholz
Arch Intern Med. 2009;169(21):1976-1985.
ABSTRACT | FULL TEXT  

Bringing the FDA's Information to Market: Comment on "Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data"
Steven Woloshin and Lisa M. Schwartz
Arch Intern Med. 2009;169(21):1985-1987.
EXTRACT | FULL TEXT  

Direct-to-Consumer Offers for Free and Discounted Medications on the Internet: A Content Analysis of "e-Samples"
Arch Intern Med. 2009;169(21):2024-2030.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Bringing the FDA's Information to Market: Comment on "Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data"
Woloshin and Schwartz
Arch Intern Med 2009;169:1985-1987.
FULL TEXT